Critical Analysis of Bladder Sparing with Trimodal Therapy in Muscle-invasive Bladder Cancer: A Systematic Review

Siegel, 2012, Cancer statistics, 2012, CA Cancer J Clin, 62, 10, 10.3322/caac.20138 Stenzl, 2011, Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines, Eur Urol, 59, 1009, 10.1016/j.eururo.2011.03.023 Gakis, 2013, ICUD-EAU International Consultation on Bladder Cancer 2012: radical cystectomy and bladder preservation for muscle-invasive urothelial carcinoma of the bladder, Eur Urol, 63, 45, 10.1016/j.eururo.2012.08.009 Shabsigh, 2009, Defining early morbidity of radical cystectomy for patients with bladder cancer using a standardized reporting methodology, Eur Urol, 55, 164, 10.1016/j.eururo.2008.07.031 Donat, 2009, Potential impact of postoperative early complications on the timing of adjuvant chemotherapy in patients undergoing radical cystectomy: a high-volume tertiary cancer center experience, Eur Urol, 55, 177, 10.1016/j.eururo.2008.07.018 Gray, 2013, Use of potentially curative therapies for muscle-invasive bladder cancer in the United States: results from the National Cancer Database, Eur Urol, 63, 823, 10.1016/j.eururo.2012.11.015 Munro, 2010, A 10-year retrospective review of a nonrandomized cohort of 458 patients undergoing radical radiotherapy or cystectomy in Yorkshire, UK, Int J Radiat Oncol Biol Phys, 77, 119, 10.1016/j.ijrobp.2009.04.050 Huddart, 2010, Life and death of spare (selective bladder preservation against radical excision): reflections on why the spare trial closed, BJU Int, 106, 753, 10.1111/j.1464-410X.2010.09537.x Kozak, 2012, Bladder preservation for localized muscle-invasive bladder cancer: the survival impact of local utilization rates of definitive radiotherapy, Int J Radiat Oncol Biol Phys, 83, 197, 10.1016/j.ijrobp.2011.12.038 Moher, 2009, Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement, J Clin Epidemiol, 62, 1006, 10.1016/j.jclinepi.2009.06.005 Shipley, 2003, Overview of bladder cancer trials in the Radiation Therapy Oncology Group, Cancer, 97, 2115, 10.1002/cncr.11282 Moonen, 1998, Muscle-invasive bladder cancer treated with external beam radiotherapy: pretreatment prognostic factors and the predictive value of cystoscopic re-evaluation during treatment, Radiother Oncol, 49, 149, 10.1016/S0167-8140(98)00089-9 Efstathiou, 2012, Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: the MGH experience, Eur Urol, 61, 705, 10.1016/j.eururo.2011.11.010 James, 2012, Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer, N Engl J Med, 366, 1477, 10.1056/NEJMoa1106106 Kaufman, 2000, Oncologist, 5, 471, 10.1634/theoncologist.5-6-471 Housset, 1993, Combined radiation and chemotherapy for invasive transitional-cell carcinoma of the bladder: a prospective study, J Clin Oncol, 11, 2150, 10.1200/JCO.1993.11.11.2150 Hagan, 2003, RTOG 97-06: initial report of a phase I–II trial of selective bladder conservation using TURBT, twice-daily accelerated irradiation sensitized with cisplatin, and adjuvant MCV combination chemotherapy, Int J Radiat Oncol Biol Phys, 57, 665, 10.1016/S0360-3016(03)00718-1 Horwich, 2005, A randomised trial of accelerated radiotherapy for localised invasive bladder cancer, Radiother Oncol, 75, 34, 10.1016/j.radonc.2004.11.003 Choudhury, 2011, Phase II study of conformal hypofractionated radiotherapy with concurrent gemcitabine in muscle-invasive bladder cancer, J Clin Oncol, 29, 733, 10.1200/JCO.2010.31.5721 Tunio, 2012, Whole-pelvis or bladder-only chemoradiation for lymph node-negative invasive bladder cancer: single-institution experience, Int J Radiat Oncol Biol Phys, 82, 457, 10.1016/j.ijrobp.2011.05.051 Efstathiou, 2009, Late pelvic toxicity after bladder-sparing therapy in patients with invasive bladder cancer: RTOG 89-03, 95-06, 97-06, 99-06, J Clin Oncol, 27, 4055, 10.1200/JCO.2008.19.5776 Huddart, 2013, Randomized noninferiority trial of reduced high-dose volume versus standard volume radiation therapy for muscle-invasive bladder cancer: results of the BC2001 trial (CRUK/01/004), Int J Radiat Oncol Biol Phys, 87, 261, 10.1016/j.ijrobp.2013.06.2044 Foroudi, 2012, Bladder cancer radiotherapy margins: a comparison of daily alignment using skin, bone or soft tissue, Clin Oncol, 24, 673, 10.1016/j.clon.2012.06.012 Hata, 2006, Proton beam therapy for invasive bladder cancer: a prospective study of bladder-preserving therapy with combined radiotherapy and intra-arterial chemotherapy, Int J Radiat Oncol Biol Phys, 64, 1371, 10.1016/j.ijrobp.2005.10.023 Loehrer, 1992, A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study, J Clin Oncol, 10, 1066, 10.1200/JCO.1992.10.7.1066 Dunst, 1994, Organ-sparing treatment of advanced bladder cancer: a 10-year experience, Int J Radiat Oncol Biol Phys, 30, 261, 10.1016/0360-3016(94)90003-5 Shipley, 1987, Treatment of invasive bladder cancer by cisplatin and radiation in patients unsuited for surgery, JAMA, 258, 931, 10.1001/jama.1987.03400070069037 Coppin, 1996, Improved local control of invasive bladder cancer by concurrent cisplatin and preoperative or definitive radiation. The National Cancer Institute of Canada Clinical Trials Group, J Clin Oncol, 14, 2901, 10.1200/JCO.1996.14.11.2901 Rödel, 2002, Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results, J Clin Oncol, 20, 3061, 10.1200/JCO.2002.11.027 Weiss, 2007, Radiochemotherapy with cisplatin and 5-fluorouracil after transurethral surgery in patients with bladder cancer, Int J Radiat Oncol Biol Phys, 68, 1072, 10.1016/j.ijrobp.2007.01.054 Chung, 2007, Long-term outcome of radiation-based conservation therapy for invasive bladder cancer, Urol Oncol, 25, 303, 10.1016/j.urolonc.2006.09.015 Danesi, 1997, Combined treatment of invasive bladder carcinoma with transurethral resection, induction chemotherapy, and radical radiotherapy plus concomitant protracted infusion of cisplatin and 5-fluorouracil: a phase I study, Cancer, 80, 1464, 10.1002/(SICI)1097-0142(19971015)80:8<1464::AID-CNCR14>3.0.CO;2-3 Nichols, 2000, Radiation therapy and concomitant paclitaxel/carboplatin chemotherapy for muscle invasive transitional cell carcinoma of the bladder: a well-tolerated combination, Int J Cancer, 90, 281, 10.1002/1097-0215(20001020)90:5<281::AID-IJC5>3.0.CO;2-U Mitin, 2013, Lancet Oncol, 14, 863, 10.1016/S1470-2045(13)70255-9 Kaufman, 2009, Phase I–II RTOG study (99–06) of patients with muscle-invasive bladder cancer undergoing transurethral surgery, paclitaxel, cisplatin, and twice-daily radiotherapy followed by selective bladder preservation or radical cystectomy and adjuvant chemotherapy, Urology, 73, 833, 10.1016/j.urology.2008.09.036 Onozawa, 2012, Analysis of intravesical recurrence after bladder-preserving therapy for muscle-invasive bladder cancer, Jpn J Clin Oncol, 42, 825, 10.1093/jjco/hys105 Eapen, 2004, Effective bladder sparing therapy with intra-arterial cisplatin and radiotherapy for localized bladder cancer, J Urol, 172, 1276, 10.1097/01.ju.0000140456.42509.b6 Wittlinger, 2009, Quadrimodal treatment of high-risk T1 and T2 bladder cancer: transurethral tumor resection followed by concurrent radiochemotherapy and regional deep hyperthermia, Radiother Oncol, 93, 358, 10.1016/j.radonc.2009.09.018 Hussain, 2004, Long-term results of a phase II study of synchronous chemoradiotherapy in advanced muscle invasive bladder cancer, Br J Cancer, 90, 2106, 10.1038/sj.bjc.6601852 1996, UK Co-ordinating Committee on Cancer Research, Lancet, 348, 1049 Caffo, 2003, Phase I study of gemcitabine and radiotherapy plus cisplatin after transurethral resection as conservative treatment for infiltrating bladder cancer, Int J Radiat Oncol Biol Phys, 57, 1310, 10.1016/S0360-3016(03)00763-6 Oh, 2009, Combined-modality therapy with gemcitabine and radiation therapy as a bladder preservation strategy: long-term results of a phase I trial, Int J Radiat Oncol Biol Phys, 74, 511, 10.1016/j.ijrobp.2008.08.021 Hoskin, 2010, Radiotherapy with concurrent carbogen and nicotinamide in bladder carcinoma, J Clin Oncol, 28, 4912, 10.1200/JCO.2010.28.4950 Pollack, 1994, Muscle-invasive bladder cancer treated with external beam radiotherapy: prognostic factors, Int J Radiat Oncol Biol Phys, 30, 267, 10.1016/0360-3016(94)90004-3 Leibovici, 2007, Organ preservation for muscle-invasive bladder cancer by transurethral resection, Urology, 70, 473, 10.1016/j.urology.2007.05.007 Herr, 2001, Transurethral resection of muscle-invasive bladder cancer: 10-year outcome, J Clin Oncol, 19, 89, 10.1200/JCO.2001.19.1.89 Solsona, 2010, Feasibility of radical transurethral resection as monotherapy for selected patients with muscle invasive bladder cancer, J Urol, 184, 475, 10.1016/j.juro.2010.04.008 Herr, 2008, Outcome of patients who refuse cystectomy after receiving neoadjuvant chemotherapy for muscle-invasive bladder cancer, Eur Urol, 54, 126, 10.1016/j.eururo.2007.12.031 Solsona, 2009, Bladder preservation in selected patients with muscle-invasive bladder cancer by complete transurethral resection of the bladder plus systemic chemotherapy: long-term follow-up of a phase 2 nonrandomized comparative trial with radical cystectomy, Eur Urol, 55, 911, 10.1016/j.eururo.2008.08.027 Hussain, 2001, Combination cisplatin, 5-fluorouracil and radiation therapy for locally advanced unresectable or medically unfit bladder cancer cases: a Southwest Oncology Group Study, J Urol, 165, 56, 10.1097/00005392-200101000-00014 Lagrange, 2011, Quality of life assessment after concurrent chemoradiation for invasive bladder cancer: results of a multicenter prospective study (GETUG 97-015), Int J Radiat Oncol Biol Phys, 79, 172, 10.1016/j.ijrobp.2009.10.038 Chauvet, 1996, Concurrent cisplatin and radiotherapy for patients with muscle invasive bladder cancer who are not candidates for radical cystectomy, J Urol, 156, 1258, 10.1016/S0022-5347(01)65563-0 Einstein, 1996, Combination transurethral resection, systemic chemotherapy, and pelvic radiotherapy for invasive (T2-T4) bladder cancer unsuitable for cystectomy: a phase I/II Southwestern Oncology Group study, Urology, 47, 652, 10.1016/S0090-4295(96)00019-2 Koga, 2013, Sensitivity to chemoradiation predicts development of metastasis in muscle-invasive bladder cancer patients, Urol Oncol, 37, 1270, 10.1016/j.urolonc.2012.01.014 Donat, 1996, Methotrexate, vinblastine, doxorubicin and cisplatin chemotherapy and cystectomy for unresectable bladder cancer, J Urol, 156, 368, 10.1016/S0022-5347(01)65852-X Gogna, 2006, Efficacy and tolerability of concurrent weekly low dose cisplatin during radiation treatment of localised muscle invasive bladder transitional cell carcinoma: a report of two sequential phase II studies from the Trans Tasman Radiation Oncology Group, Radiother Oncol, 81, 9, 10.1016/j.radonc.2006.09.001 Kragelj, 2005, Phase II study of radiochemotherapy with vinblastine in invasive bladder cancer, Radiother Oncol, 75, 44, 10.1016/j.radonc.2005.01.007 Shipley, 1998, Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of Radiation Therapy Oncology Group 89-03, J Clin Oncol, 16, 3576, 10.1200/JCO.1998.16.11.3576 Zapatero, 2012, Long-term results of two prospective bladder-sparing trimodality approaches for invasive bladder cancer: neoadjuvant chemotherapy and concurrent radio-chemotherapy, Urology, 80, 1056, 10.1016/j.urology.2012.07.045 Aboziada, 2009, Initial results of bladder preserving approach by chemo-radiotherapy in patients with muscle invading transitional cell carcinoma, J Egypt Natl Canc Inst, 21, 167 Peyromaure, 2004, Concurrent chemoradiotherapy for clinical stage T2 bladder cancer: report of a single institution, Urology, 63, 73, 10.1016/j.urology.2003.09.018 Varveris, 1997, Concurrent platinum and docetaxel chemotherapy and external radical radiotherapy in patients with invasive transitional cell bladder carcinoma. A preliminary report of tolerance and local control, Anticancer Res, 17, 4771 Tester, 1993, Combined modality program with possible organ preservation for invasive bladder carcinoma: results of RTOG protocol 85-12, Int J Radiat Oncol Biol Phys, 25, 783, 10.1016/0360-3016(93)90306-G Rotman, 1990, Treatment of advanced transitional cell carcinoma of the bladder with irradiation and concomitant 5-fluorouracil infusion, Int J Radiat Oncol Biol Phys, 18, 1131, 10.1016/0360-3016(90)90449-T Russell, 1990, Combined 5-fluorouracil and irradiation for transitional cell carcinoma of the urinary bladder, Int J Radiat Oncol Biol Phys, 19, 693, 10.1016/0360-3016(90)90498-9 Shipley, 2002, Selective bladder preservation by combined modality protocol treatment: long-term outcomes of 190 patients with invasive bladder cancer, Urology, 60, 62, 10.1016/S0090-4295(02)01650-3 Kotwal, 2008, Similar treatment outcomes for radical cystectomy and radical radiotherapy in invasive bladder cancer treated at a United Kingdom specialist treatment center, Int J Radiat Oncol Biol Phys, 70, 456, 10.1016/j.ijrobp.2007.06.030 Madersbacher, 2003, Radical cystectomy for bladder cancer today—a homogeneous series without neoadjuvant therapy, J Clin Oncol, 21, 690, 10.1200/JCO.2003.05.101 Hautmann, 2012, Radical cystectomy for urothelial carcinoma of the bladder without neoadjuvant or adjuvant therapy: long-term results in 1100 patients, Eur Urol, 61, 1039, 10.1016/j.eururo.2012.02.028 Culp, 2014, Refining patient selection for neoadjuvant chemotherapy before radical cystectomy, J Urol, 191, 40, 10.1016/j.juro.2013.07.061 Bekelman, 2013, Radical cystectomy versus bladder-preserving therapy for muscle-invasive urothelial carcinoma: examining confounding and misclassification bias in cancer observational comparative effectiveness research, Value Health, 16, 610, 10.1016/j.jval.2013.01.005 Griffiths, 2011, International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial, J Clin Oncol, 29, 2171, 10.1200/JCO.2010.32.3139 Svatek, 2011, Discrepancy between clinical and pathological stage: external validation of the impact on prognosis in an international radical cystectomy cohort, BJU Int, 107, 898, 10.1111/j.1464-410X.2010.09628.x Yafi, 2011, Contemporary outcomes of 2287 patients with bladder cancer who were treated with radical cystectomy: a Canadian multicentre experience, BJU Int, 108, 539, 10.1111/j.1464-410X.2010.09912.x Grossman, 2003, Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer, N Engl J Med, 349, 859, 10.1056/NEJMoa022148 Shipley, 1985, Full-dose irradiation for patients with invasive bladder carcinoma: clinical and histological factors prognostic of improved survival, J Urol, 134, 679, 10.1016/S0022-5347(17)47381-2 Coen, 2013, Nomograms predicting response to therapy and outcomes after bladder-preserving trimodality therapy for muscle-invasive bladder cancer, Int J Radiat Oncol Biol Phys, 86, 311, 10.1016/j.ijrobp.2013.01.020 Fung, 1991, Prognostic factors in invasive bladder carcinoma in a prospective trial of preoperative adjuvant chemotherapy and radiotherapy, J Clin Oncol, 9, 1533, 10.1200/JCO.1991.9.9.1533 Tester, 1996, Neoadjuvant combined modality program with selective organ preservation for invasive bladder cancer: results of Radiation Therapy Oncology Group phase II trial 8802, J Clin Oncol, 14, 119, 10.1200/JCO.1996.14.1.119 Danesi, 2004, Conservative treatment of invasive bladder carcinoma by transurethral resection, protracted intravenous infusion chemotherapy, and hyperfractionated radiotherapy: long term results, Cancer, 101, 2540, 10.1002/cncr.20654 Arias, 2000, Chemoradiotherapy for muscle invading bladder carcinoma. Final report of a single institutional organ-sparing program, Int J Radiat Oncol Biol Phys, 47, 373, 10.1016/S0360-3016(00)00444-2 Perdonà, 2008, Bladder-sparing, combined-modality approach for muscle-invasive bladder cancer: a multi-institutional, long-term experience, Cancer, 112, 75, 10.1002/cncr.23137 Sabaa, 2010, Combined modality treatment with bladder preservation for muscle invasive bladder cancer, Urol Oncol, 28, 14, 10.1016/j.urolonc.2008.07.005 Krause, 2011, 15-year survival rates after transurethral resection and radiochemotherapy or radiation in bladder cancer treatment, Anticancer Res, 31, 985 May, 2013, Gender-specific differences in cancer-specific survival after radical cystectomy for patients with urothelial carcinoma of the urinary bladder in pathologic tumor stage T4a, Urol Oncol, 31, 1141, 10.1016/j.urolonc.2011.09.011 Keck, 2013, Female sex is an independent risk factor for reduced overall survival in bladder cancer patients treated by transurethral resection and radio- or radiochemotherapy, World J Urol, 31, 1023, 10.1007/s00345-012-0971-5 Zietman, 1998, A phase I/II trial of transurethral surgery combined with concurrent cisplatin, 5-fluorouracil and twice daily radiation followed by selective bladder preservation in operable patients with muscle invading bladder cancer, J Urol, 160, 1673, 10.1016/S0022-5347(01)62379-6 Lin, 2009, Induction cisplatin and fluorouracil-based chemotherapy followed by concurrent chemoradiation for muscle-invasive bladder cancer, Int J Radiat Oncol Biol Phys, 75, 442, 10.1016/j.ijrobp.2008.11.030 Kachnic, 1997, Bladder preservation by combined modality therapy for invasive bladder cancer, J Clin Oncol, 15, 1022, 10.1200/JCO.1997.15.3.1022 Tilki, 2013, Lymphovascular invasion is independently associated with bladder cancer recurrence and survival in patients with final stage T1 disease and negative lymph nodes after radical cystectomy, BJU Int, 111, 1215, 10.1111/j.1464-410X.2012.11455.x Watts, 2011, Prognostic implications of lymph node involvement in bladder cancer: are we understaging using current methods?, BJU Int, 108, 484, 10.1111/j.1464-410X.2011.10330.x Gospodarowicz, 1989, Radical radiotherapy for muscle invasive transitional cell carcinoma of the bladder: failure analysis, J Urol, 142, 1448, 10.1016/S0022-5347(17)39122-X Smith, 2013, Bladder preservation in the treatment of muscle-invasive bladder cancer (MIBC): a review of the literature and a practical approach to therapy, BJU Int, 112, 13, 10.1111/j.1464-410X.2012.11762.x Fellin, 1997, Combined chemotherapy and radiation with selective organ preservation for muscle-invasive bladder carcinoma. A single-institution phase II study, Br J Urol, 80, 44, 10.1046/j.1464-410X.1997.00221.x Cobo, 2006, Conservative treatment with transurethral resection, neoadjuvant chemotherapy followed by radiochemotherapy in stage T2–3 transitional bladder cancer, Clin Transl Oncol, 8, 903, 10.1007/s12094-006-0154-1 2005, Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data, Eur Urol, 48, 202, 10.1016/j.eururo.2005.04.006 Glynne-Jones, 2007, Neoadjuvant cisplatin chemotherapy before chemoradiation: a flawed paradigm?, J Clin Oncol, 25, 5281, 10.1200/JCO.2007.12.3133 Chen, 2003, Concurrent cisplatin, 5-fluorouracil, leucovorin, and radiotherapy for invasive bladder cancer, Int J Radiat Oncol Biol Phys, 56, 726, 10.1016/S0360-3016(03)00124-X Weiss, 2008, Management of superficial recurrences in an irradiated bladder after combined-modality organ-preserving therapy, Int J Radiat Oncol Biol Phys, 70, 1502, 10.1016/j.ijrobp.2007.08.007 Zietman, 2001, Selective bladder conservation using transurethral resection, chemotherapy, and radiation: management and consequences of Ta, T1, and Tis recurrence within the retained bladder, Urology, 58, 380, 10.1016/S0090-4295(01)01219-5 Herr, 1997, Tumour progression and survival in patients with T1G3 bladder tumours: 15-year outcome, Br J Urol, 80, 762, 10.1046/j.1464-410X.1997.00431.x Eswara, 2012, Complications and long-term results of salvage cystectomy after failed bladder sparing therapy for muscle invasive bladder cancer, J Urol, 187, 463, 10.1016/j.juro.2011.09.159 Iwai, 2011, Perioperative complications of radical cystectomy after induction chemoradiotherapy in bladder-sparing protocol against muscle-invasive bladder cancer: a single institutional retrospective comparative study with primary radical cystectomy, Jpn J Clin Oncol, 41, 1373, 10.1093/jjco/hyr150 Zietman, 2003, Organ conservation in invasive bladder cancer by transurethral resection, chemotherapy and radiation: results of a urodynamic and quality of life study on long-term survivors, J Urol, 170, 1772, 10.1097/01.ju.0000093721.23249.c3 Herman, 2004, Prospective quality-of-life assessment in patients receiving concurrent gemcitabine and radiotherapy as a bladder preservation strategy, Urology, 64, 69, 10.1016/j.urology.2004.02.024 Caffo, 1996, Assessment of quality of life after cystectomy or conservative therapy for patients with infiltrating bladder carcinoma. A survey by a self-administered questionnaire, Cancer, 78, 1089, 10.1002/(SICI)1097-0142(19960901)78:5<1089::AID-CNCR20>3.0.CO;2-Y Henningsohn, 2002, Distressful symptoms after radical radiotherapy for urinary bladder cancer, Radiother Oncol, 62, 215, 10.1016/S0167-8140(01)00455-8 Tran, 2009, Bladder conservation treatment in the elderly population: results and prognostic factors of muscle-invasive bladder cancer, Am J Clin Oncol, 32, 333, 10.1097/COC.0b013e31818b9486 Chamie, 2008, Cystectomy in the elderly: does the survival benefit in younger patients translate to the octogenarians?, BJU Int, 102, 284, 10.1111/j.1464-410X.2008.07636.x Gore, 2010, Use of radical cystectomy for patients with invasive bladder cancer, J Natl Cancer Inst, 102, 802, 10.1093/jnci/djq121 Hollenbeck, 2004, Aggressive treatment for bladder cancer is associated with improved overall survival among patients 80 years old or older, Urology, 64, 292, 10.1016/j.urology.2004.03.034 Svatek, 2012, Role and extent of lymphadenectomy during radical cystectomy for invasive bladder cancer, Curr Urol Rep, 13, 115, 10.1007/s11934-012-0235-3 Eisenberg, 2010, Early complications of cystectomy after high dose pelvic radiation, J Urol, 184, 2264, 10.1016/j.juro.2010.08.007 Choudhury, 2010, MRE11 expression is predictive of cause-specific survival following radical radiotherapy for muscle-invasive bladder cancer, Cancer Res, 70, 7017, 10.1158/0008-5472.CAN-10-1202 Chakravarti, 2005, Int J Radiat Oncol Biol Phys, 62, 309, 10.1016/j.ijrobp.2004.09.047 Lautenschlaeger, 2013, Bladder preservation therapy for muscle-invading bladder cancers on Radiation Therapy Oncology Group trials 8802, 8903, 9506, and 9706: vascular endothelial growth factor B overexpression predicts for increased distant metastasis and shorter survival, Oncologist, 18, 685, 10.1634/theoncologist.2012-0461 Laurberg, 2012, Expression of TIP60 (tat-interactive protein) and MRE11 (meiotic recombination 11 homolog) predict treatment-specific outcome of localised invasive bladder cancer, BJU Int, 110, 1228, 10.1111/j.1464-410X.2012.11564.x Agerbaek, 2003, Retinoblastoma protein expression is an independent predictor of both radiation response and survival in muscle-invasive bladder cancer, Br J Cancer, 89, 298, 10.1038/sj.bjc.6601063 Garcia del Muro, 2004, p53 and p21 expression levels predict organ preservation and survival in invasive bladder carcinoma treated with a combined-modality approach, Cancer, 100, 1859, 10.1002/cncr.20200 Moonen, 2001, Apoptosis, proliferation and p53, cyclin D1, and retinoblastoma gene expression in relation to radiation response in transitional cell carcinoma of the bladder, Int J Radiat Oncol Biol Phys, 49, 1305, 10.1016/S0360-3016(00)01503-0 Koga, 2011, ErbB2 and NFκB overexpression as predictors of chemoradiation resistance and putative targets to overcome resistance in muscle-invasive bladder cancer, PLoS One, 6, 27616, 10.1371/journal.pone.0027616 Yoshida, 2012, Role of diffusion-weighted magnetic resonance imaging in predicting sensitivity to chemoradiotherapy in muscle-invasive bladder cancer, Int J Radiat Oncol Biol Phys, 83, 21, 10.1016/j.ijrobp.2011.11.065